Business Wire

Chugai's HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche has received regulatory approval from the European Commission for HEMLIBRA ® (emicizumab) for routine prophylaxis of bleeding episodes in people with hemophilia A with factor VIII inhibitors.

“Following the US approval, we are very proud of the approval to deliver the first-in-class product HEMLIBRA to people with hemophilia A with inhibitors in the EU as well,” said Chugai’s President & COO, Tatsuro Kosaka. “By having HEMLIBRA – an additional Chugai originated medicine to the existing product lineup currently marketed in the EU, such as RoACTEMRA ® and ALECENSA ® , we are continuously committed to resolve unmet medical needs for patients in the EU jointly with Roche.”

This approval is based on the two pivotal studies for hemophilia A with inhibitors: the results of HAVEN1 study (NCT02622321) for adolescents and adults, and the interim analysis of HAVEN2 study (NCT02795767) in children.

HEMLIBRA is a bispecific monoclonal antibody, which was developed using Chugai’s proprietary antibody engineering technologies. The drug is designed to bind factor IXa and factor X. In doing so, HEMLIBRA provides the cofactor function of factor VIII in people with hemophilia A, who either lack or have impaired coagulation function of factor VIII1, 2). In November 2017, the drug (US product name: HEMLIBRA®; Genentech) was approved by the U.S. Food and Drug Administration and was marketed for “routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.” In Japan, HEMLIBRA obtained an orphan drug designation in August 2016 from the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) who developed inhibitors to factor VIII, followed by an application for regulatory approval filed in July 2017.

About the results of HAVEN1 study and HAVEN2 study

Press release issued on June 26, 2017
https://www.chugai-pharm.co.jp/english/news/detail/20170626140000.html

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

Trademarks used or mentioned in this release are protected by law.

References

1) Kitazawa, et al. Nature Medicine 2012; 18(10): 1570
2) Sampei, et al. PLoS ONE 2013; 8: e57479

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Panasonic’s Next-generation HD-PLC®*1, BPL Communication Technology Adopted as IEEE 1901a Standard25.3.2019 02:14:00 CETPressemelding

On March 25, 2019, Panasonic Corporation announced that the IEEE Standards Association has approved the company’s next-generation broadband over powerline (BPL) communication technology for Internet of Things (IoT) as the IEEE 1901a Standard on March 21, 2019 at the Standards Board meeting in Munich, Germany. The company proposed the technology to the IEEE Standardization 1901a Working Group*2 in June 2018. This standard flexibly meets various demands for IoT-related services. IEEE 1901a, BPL communication standard for IoT enables to control frequency bands according to usage. It allows scalable communications with features to extend communication distances and to select speeds. The flexible features defined in this standard enable to address the diverse communication needs of IoT-related services. It implements the following new functions based on the Panasonic original HD-PLC ® Wavelet OFDM technology (standard mode), already adopted in the IEEE 1901-2010 standard. The standard mode

Earth Networks Launches Aviation Early Warning System for the Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA)24.3.2019 23:00:00 CETPressemelding

Earth Networks today announced it has completed a new aviation early weather warning system for The Agency for the Safety of Air Navigation in Africa and Madagascar (ASECNA). The announcement was made at the 6th annual InterMET Asia conference in Singapore. Designed for air traffic management and airport operations professionals to issue alerts on severe weather and lightning threats that have the potential to affect air and land operations including ground crews, fueling, and aircraft, the newly operational global aviation early warning system includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network, featuring over 1,700 sensors in more than 100 countries On-the-ground weather monitoring via the Earth Networks Weather Network Sferic Maps, a web-based severe weather monitoring and alerting platform Severe weather data and visualization tools such as Dangerous Thunderstorm Alerts and PulseRad, a lightning-derived radar alternative Short-range point f

PIVOT Fintech Gets Capital Markets Services License From The Monetary Authority Of Singapore24.3.2019 21:30:00 CETPressemelding

PIVOT Fintech Pte. Ltd. (“PIVOT”), the digital wealth management technology services venture backed by Pintec Technology Holdings Ltd. (“PINTEC”; NASDAQ: PT) and FWD Group announced today that it has been granted a Capital Markets Services (“CMS”) license by the Monetary Authority of Singapore (MAS). PIVOT’s CMS license, which comes after the recently published MAS Guidelines on the Provision of Digital Advisory Services on 8 October 2018, allows the company to offer AI-driven investment services directly to retail clients. “This significant Singapore milestone marks the start of PIVOT’s ambition to deliver innovative wealth management solutions in Southeast Asia,” said PIVOT CEO Victor Lye, who created PIVOT’s proprietary gamified risk profiling analytics to drive financial inclusiveness. PIVOT’s core shareholder, PINTEC, has proven technology and expertise in delivering AI-driven global asset allocation and money management services to financial institutions in the highly competitive

1.1 Million People Benefit from the UAE-based Big Heart Foundation’s Humanitarian Efforts in 201824.3.2019 19:21:00 CETPressemelding

Humanitarian aid worth US$ 15.8 million (AED 58 million) to 1,091,000 million refugees, internally displaced and acutely disadvantaged people in 12 conflict-laden nations worldwide has been offered by The Big Heart Foundation (TBHF), a leading international humanitarian organisation based in Sharjah, UAE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190324005019/en/ (TBHF Graphic) Operating under the leadership of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, UNHCR Eminent Advocate and TBHF Chairperson, the humanitarian non-profit operating out of Sharjah – the third largest emirate in United Arab Emirates (UAE) – has mobilised the funds to support and initiate 20 projects in collaboration with UNHCR, Doctors without Borders (Médecins Sans Frontières) in vital sectors of food security, healthcare and education. Their 2018 efforts spanned 12 countries, namely, Bangladesh, Egypt, Iraq, Jordan, Malaysia, Pakistan, Pal

SCG Chemicals Company chooses gPROMS modelling for digital design and operations22.3.2019 15:55:00 CETPressemelding

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced that it has signed a long-term agreement with SCG, one of the largest integrated petrochemical companies in South East Asia, to standardise on PSE’s gPROMS® modelling technology for digital design and operations. SCG applies advanced process models within digital design initiatives to explore the process decision space rapidly and effectively, in order to reduce uncertainty and make better, faster and safer design and operating decisions. This help them to accelerate innovation and optimise the design and operation of their process plants. Dr Suracha Udomsak, SCG’s Emerging Business Director and R&D Director, says, “at SCG Chemicals, advanced process modelling (APM) is a key element in our Digital Manufacturing platform. APM accelerates innovation by making the development workflow ‘faster, cheaper & safer’, which are key considerations for us. It is a core technology building block that enables u

Logicor Announces Results for Year Ended 31 December 201822.3.2019 14:29:00 CETPressemelding

Logicor announces strong financial performance for the year ended 31 December Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%). Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe. EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps). LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x. Capital Structure In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of